Hong, D. S., Bang, Y.-J., Barlesi, F., Durm, G., Falchook, G., Govindan, R., … Li, B. T. (2021). MO01.31 Durability of Clinical Benefit and Biomarkers in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Sotorasib, a KRAS(G12C) Inhibitor. In Journal of Thoracic Oncology (Vol. 16, pp. S28–S29). Elsevier BV. https://doi.org/10.1016/j.jtho.2020.10.136

Hong, D. S., Y. -. J. Bang, F. Barlesi, G. Durm, G. Falchook, R. Govindan, G. Dy, et al. “MO01.31 Durability of Clinical Benefit and Biomarkers in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Sotorasib, a KRAS(G12C) Inhibitor.” In Journal of Thoracic Oncology, 16:S28–29. Elsevier BV, 2021. https://doi.org/10.1016/j.jtho.2020.10.136.

Hong DS, Bang Y-J, Barlesi F, Durm G, Falchook G, Govindan R, et al. MO01.31 Durability of Clinical Benefit and Biomarkers in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Sotorasib, a KRAS(G12C) Inhibitor. In: Journal of Thoracic Oncology. Elsevier BV; 2021. p. S28–9.

Hong, D. S., et al. “MO01.31 Durability of Clinical Benefit and Biomarkers in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Sotorasib, a KRAS(G12C) Inhibitor.” Journal of Thoracic Oncology, vol. 16, no. 1, Elsevier BV, 2021, pp. S28–29. Crossref, doi:10.1016/j.jtho.2020.10.136.

Hong DS, Bang Y-J, Barlesi F, Durm G, Falchook G, Govindan R, Dy G, Park K, Strickler J, Burns T, Kim J, Ang A, Lipford JR, Ngarmchamnanrith G, Anderson A, Li BT. MO01.31 Durability of Clinical Benefit and Biomarkers in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Sotorasib, a KRAS(G12C) Inhibitor. Journal of Thoracic Oncology. Elsevier BV; 2021. p. S28–S29.